Pan Tumor Rollover Study
NCT03899155 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1500
Last updated 2026-04-01
Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions
Interventions
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Trametinib
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Nivolumab + Relatlimab
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Rucaparib
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Regorafinib
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Sunitinib
Specified dose on specified days
- DRUG
-
Pemetrexed
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- collaborator INDUSTRY
- collaborator INDUSTRY
-
Clovis Oncology, Inc.
collaborator INDUSTRY -
Janssen Pharmaceuticals
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-09
- Primary Completion
- 2029-08-25
- Completion
- 2029-08-25
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- Czechia
- Denmark
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- Ireland
- Israel
- Italy
- Japan
- Mexico
- Netherlands
- New Zealand
- Norway
- Peru
- Poland
- Portugal
- Puerto Rico
- Romania
- Russia
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
NCT03484819 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968109 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
NCT03138512 ·Status: COMPLETED ·Phase: PHASE3
-
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075553 ·Status: TERMINATED ·Phase: PHASE2
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
NCT00918333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
NCT04205409 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
NCT02996110 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
NCT02159755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
NCT03440567 ·Status: COMPLETED ·Phase: PHASE1
-
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00962507 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
NCT05272384 ·Status: RECRUITING ·Phase: PHASE1
-
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT03229278 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
NCT01703481 ·Status: COMPLETED ·Phase: PHASE1
-
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
NCT00967044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT05927571 ·Status: RECRUITING ·Phase: PHASE1
-
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03849469 ·Status: COMPLETED ·Phase: PHASE1
-
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
NCT06489808 ·Status: RECRUITING ·Phase: PHASE2
-
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT06905509 ·Status: RECRUITING ·Phase: PHASE2
-
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085 ·Status: RECRUITING ·Phase: PHASE1